SPRO

Spero Therapeutics, Inc. SEC filings

Every EDGAR filing for Spero Therapeutics, Inc. (SPRO), newest first, with AI summaries and stories.

Ticker: SPRO
CIK: 1701108
Latest filing: Sep 11

Next: earnings expected ~Nov 12 · 10-Q expected ~Nov 12 (deadline Nov 16) · usually files the same day as earnings

Watch in the app Get the app

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

ROUTINEEFFECTSpero Therapeutics, Inc.SPROSep 11
Registration declared effective
Company Filing
ROUTINE8-KSpero Therapeutics, Inc.SPROAug 28
Current report
Company Filing
ROUTINES-3Spero Therapeutics, Inc.SPROAug 28
Securities offering
Company Filing
ROUTINE8-KSpero Therapeutics, Inc.SPROAug 12
Current report
Company Filing
NOTABLE10-QSpero Therapeutics, Inc.SPROAug 12
Quarterly report
Company Filing
ROUTINE4Spero Therapeutics, Inc.SPROAug 6
2 insider filings
Debra Zack, insider filing for SPRO
Show all 2
- 4Insider filing for SPROAug 6
- 3New insider at SPROAug 6
Debra Zack, reporting
ROUTINE8-KSpero Therapeutics, Inc.SPROJul 14
Current report
Company Filing
ROUTINE4Spero Therapeutics, Inc.SPROJun 25
7 insider filings
Milind Deshpande, insider filing for SPRO
Show all 7
- 4Insider filing for SPROJun 25
- 4Insider filing for SPROJun 25
- 4Insider filing for SPROJun 25
- 4Insider filing for SPROJun 25
- 4Insider filing for SPROJun 25
- 4Insider filing for SPROJun 25
- 4Insider filing for SPROJun 25
Milind Deshpande, reporting
ROUTINE8-KSpero Therapeutics, Inc.SPROJun 25
Current report
Company Filing
ROUTINES-8Spero Therapeutics, Inc.SPROJun 23
Employee stock plan registration
Company Filing
ROUTINE8-KSpero Therapeutics, Inc.SPROJun 22
Current report
Company Filing
NOTABLE10-QSpero Therapeutics, Inc.SPROMay 13
Quarterly report
Company Filing
ROUTINE8-KSpero Therapeutics, Inc.SPROMay 13
Current report
Company Filing
ROUTINE4Spero Therapeutics, Inc.SPROMay 6
Esther Rajavelu, insider filing for SPRO
Company Filing
Esther Rajavelu, reporting
ROUTINEARSSpero Therapeutics, Inc.SPROApr 27
Annual report to shareholders
Company Filing
ROUTINEDEFA14ASpero Therapeutics, Inc.SPROApr 27
Additional proxy materials
Company Filing
ROUTINEDEF 14ASpero Therapeutics, Inc.SPROApr 27
Proxy statement
Company Filing
ROUTINEPRE 14ASpero Therapeutics, Inc.SPROApr 13
Preliminary proxy statement
Company Filing
ROUTINE8-KSpero Therapeutics, Inc.SPROMar 26
Current report
Company Filing
NOTABLE10-KSpero Therapeutics, Inc.SPROMar 26
Annual report
Company Filing
ROUTINE4Spero Therapeutics, Inc.SPROFeb 9
2 insider filings
Esther Rajavelu, insider filing for SPRO
Show all 2
- 4Insider filing for SPROFeb 9
- 4Insider filing for SPROFeb 9
Esther Rajavelu, reporting
ROUTINE4Spero Therapeutics, Inc.SPROFeb 5
Timothy Keutzer, insider filing for SPRO
Company Filing
Timothy Keutzer, reporting
ROUTINE4Spero Therapeutics, Inc.SPROFeb 4
Esther Rajavelu, insider filing for SPRO
Company Filing
Esther Rajavelu, reporting
ROUTINE8-KSpero Therapeutics, Inc.SPROJan 30
Current report
Company Filing
ROUTINE8-KSpero Therapeutics, Inc.SPRODec 19, 2025
Current report
Company Filing
MAJOR8-KSpero Therapeutics, Inc.SPRONov 13, 2025
Spero Therapeutics, Inc. (SPRO) announced the resignation of its Chief Executive Officer, effective immediately, citing strategic differences with the Board of Directors.
Company Filing
NOTABLE10-QSpero Therapeutics, Inc.SPRONov 13, 2025
Spero Therapeutics, Inc. (SPRO) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period.
Company Filing
ROUTINE4Spero Therapeutics, Inc.SPRONov 12, 2025
Esther Rajavelu, insider filing for SPRO
Company Filing
Esther Rajavelu, reporting

Older filings on EDGAR

Get an email when Spero Therapeutics, Inc. files

Filings

2 insider filings

7 insider filings

2 insider filings

Spero Therapeutics, Inc. (SPRO) announced the resignation of its Chief Executive Officer, effective immediately, citing strategic differences with the Board of Directors.

Spero Therapeutics, Inc. (SPRO) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period.